Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE Jr, Walker A, Friedman HS. Quinn JA, et al. Among authors: vredenburgh jj. Neuro Oncol. 2009 Oct;11(5):556-61. doi: 10.1215/15228517-2009-007. Epub 2009 Mar 16. Neuro Oncol. 2009. PMID: 19289491 Free PMC article. Clinical Trial.
4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.
Rizzieri DA, Talbot JT, Long GD, Vredenburgh JJ, Gasparetto C, Smith CS, Colvin MO, Adams D, Morris A, Dodge R, Loftis J, Waters-Pick B, Reese M, Carawan H, Koh LP, Chao NJ. Rizzieri DA, et al. Among authors: vredenburgh jj. Biol Blood Marrow Transplant. 2003 Mar;9(3):183-8. doi: 10.1053/bbmt.2003.50011. Biol Blood Marrow Transplant. 2003. PMID: 12652469 Free article. Clinical Trial.
Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Rich JN, et al. Among authors: vredenburgh jj. J Clin Oncol. 2004 Jan 1;22(1):133-42. doi: 10.1200/JCO.2004.08.110. Epub 2003 Nov 24. J Clin Oncol. 2004. PMID: 14638850 Clinical Trial.
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, Vredenburgh JJ, Gasparetto C, Long GD, Anderson E, Foster T, Toaso B, Adams D, Niedzwiecki D, Gockerman JP. Rizzieri DA, et al. Among authors: vredenburgh jj. Cancer. 2004 Jun 1;100(11):2408-14. doi: 10.1002/cncr.20245. Cancer. 2004. PMID: 15160345 Free article. Clinical Trial.
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. Among authors: vredenburgh jj. J Clin Oncol. 2005 Dec 20;23(36):9359-68. doi: 10.1200/JCO.2005.03.2185. J Clin Oncol. 2005. PMID: 16361636 Clinical Trial.
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. Among authors: vredenburgh jj. J Clin Oncol. 2006 Jan 1;24(1):115-22. doi: 10.1200/JCO.2005.03.4082. J Clin Oncol. 2006. PMID: 16382120 Clinical Trial.
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN. Reardon DA, et al. Among authors: vredenburgh jj. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8. doi: 10.1158/1078-0432.CCR-05-2215. Clin Cancer Res. 2006. PMID: 16467100 Clinical Trial.
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Reardon DA, et al. Among authors: vredenburgh jj. J Nucl Med. 2006 Jun;47(6):912-8. J Nucl Med. 2006. PMID: 16741299 Free article. Clinical Trial.
169 results